Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
JE Garber, S Halabi, SM Tolaney, E Kaplan, L Archer, JN Atkins, S Edge, CL Shapiro, L Dressler, EM Paskett, G Kimmick, J Orcutt, A Scalzo, E Winer, E Levine, N Shahab, N Berliner, for the Cancer and Leukemia Group B
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
J Natl Cancer Inst. 2010 Jul 7;102(13):942-949, JE Garber, S Halabi, SM Tolaney, E Kaplan, L Archer, JN Atkins, S Edge, CL Shapiro, L Dressler, EM Paskett, G Kimmick, J Orcutt, A Scalzo, E Winer, E Levine, N Shahab, N Berliner, for the Cancer and Leukemia Group B
ABSTRACT
In this pharmacogenetic study, CALGB investigators found an association between the Factor V Leiden variant and development of thromboembolism in women taking tamoxifen for early breast cancer.
